» Articles » PMID: 31673018

A Novel Nucleoside Rescue Metabolic Pathway May Be Responsible for Therapeutic Effect of Orally Administered Cordycepin

Abstract

Although adenosine and its analogues have been assessed in the past as potential drug candidates due to the important role of adenosine in physiology, only little is known about their absorption following oral administration. In this work, we have studied the oral absorption and disposition pathways of cordycepin, an adenosine analogue. In vitro biopharmaceutical properties and in vivo oral absorption and disposition of cordycepin were assessed in rats. Despite the fact that numerous studies showed efficacy following oral dosing of cordycepin, we found that intact cordycepin was not absorbed following oral administration to rats. However, 3'-deoxyinosine, a metabolite of cordycepin previously considered to be inactive, was absorbed into the systemic blood circulation. Further investigation was performed to study the conversion of 3'-deoxyinosine to cordycepin 5'-triphosphate in vitro using macrophage-like RAW264.7 cells. It demonstrated that cordycepin 5'-triphosphate, the active metabolite of cordycepin, can be formed not only from cordycepin, but also from 3'-deoxyinosine. The novel nucleoside rescue metabolic pathway proposed in this study could be responsible for therapeutic effects of adenosine and other analogues of adenosine following oral administration. These findings may have importance in understanding the physiology and pathophysiology associated with adenosine, as well as drug discovery and development utilising adenosine analogues.

Citing Articles

Cordycepin affects Streptococcus mutans biofilm and interferes with its metabolism.

Shao Y, Zhu W, Liu S, Zhang K, Sun Y, Liu Y BMC Oral Health. 2025; 25(1):25.

PMID: 39755609 PMC: 11700466. DOI: 10.1186/s12903-024-05355-7.


Targeting protein homeostasis with small molecules as a strategy for the development of pan-coronavirus antiviral therapies.

Mao Y, Jahanshahi S, Malty R, Van Ommen D, Wan Y, Morey T Commun Biol. 2024; 7(1):1460.

PMID: 39511285 PMC: 11543989. DOI: 10.1038/s42003-024-07143-z.


Cordycepin generally inhibits growth factor signal transduction in a systems pharmacology study.

Lawrence S, Lin J, Khurshid A, Utami W, Singhania R, Ashraf S FEBS Lett. 2024; 599(3):415-435.

PMID: 39508147 PMC: 11808429. DOI: 10.1002/1873-3468.15046.


Enhancing cancer immunotherapy using cordycepin and Cordyceps militaris extract to sensitize cancer cells and modulate immune responses.

Thepmalee C, Jenkham P, Ramwarungkura B, Suwannasom N, Khoothiam K, Thephinlap C Sci Rep. 2024; 14(1):21907.

PMID: 39300166 PMC: 11413023. DOI: 10.1038/s41598-024-72833-x.


Cordycepin Triphosphate as a Potential Modulator of Cellular Plasticity in Cancer via cAMP-Dependent Pathways: An In Silico Approach.

Gonzalez-Llerena J, Espinosa-Rodriguez B, Trevino-Almaguer D, Mendez-Lopez L, Carranza-Rosales P, Gonzalez-Barranco P Int J Mol Sci. 2024; 25(11).

PMID: 38891880 PMC: 11171877. DOI: 10.3390/ijms25115692.


References
1.
Cappellacci L, Barboni G, Palmieri M, Pasqualini M, Grifantini M, Costa B . Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues. J Med Chem. 2002; 45(6):1196-202. DOI: 10.1021/jm0102755. View

2.
Lee J, Adrower C, Qin C, Fischer P, de Moor C, Gershkovich P . Development of Cordycepin Formulations for Preclinical and Clinical Studies. AAPS PharmSciTech. 2017; 18(8):3219-3226. DOI: 10.1208/s12249-017-0795-0. View

3.
Kodama E, McCaffrey R, Yusa K, Mitsuya H . Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells. Biochem Pharmacol. 1999; 59(3):273-81. DOI: 10.1016/s0006-2952(99)00325-1. View

4.
Kim H, Naura A, Errami Y, Ju J, Boulares A . Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP. Mol Med. 2011; 17(9-10):893-900. PMC: 3188885. DOI: 10.2119/molmed.2011.00032. View

5.
Hartman N, Yarchoan R, Pluda J, Thomas R, Marczyk K, Broder S . Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990; 47(5):647-54. DOI: 10.1038/clpt.1990.86. View